Literature DB >> 19878641

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

Susan O'Brien1, Ellin Berman, Hossein Borghaei, Daniel J Deangelo, Marcel P Devetten, Steven Devine, Harry P Erba, Jason Gotlib, Madan Jagasia, Joseph O Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P Radich, Neil P Shah Md, Paul J Shami, B Douglas Smith, David S Snyder, Martin S Tallman, Moshe Talpaz, Meir Wetzler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19878641     DOI： 10.6004/jnccn.2009.0065

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  64 in total

1.  Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.

Authors:  François Guilhot; Timothy P Hughes; Jorge Cortes; Brian J Druker; Michele Baccarani; Insa Gathmann; Michael Hayes; Camille Granvil; Yanfeng Wang
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

2.  Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Authors:  Guillermo Garcia-Manero; Raoul Tibes; Tapan Kadia; Hagop Kantarjian; Martha Arellano; Emily A Knight; Hao Xiong; Qin Qin; Wijith Munasinghe; Lisa Roberts-Rapp; Peter Ansell; Daniel H Albert; Brian Oliver; Mark D McKee; Justin L Ricker; Hanna Jean Khoury
Journal:  Invest New Drugs       Date:  2015-05-02       Impact factor: 3.850

3.  Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.

Authors:  Sikander Ailawadhi; Luke P Akard; Carole B Miller; Anand Jillella; Daniel J DeAngelo; Solveig G Ericson; Felice Lin; Ghulam Warsi; Jerald Radich
Journal:  Ther Adv Hematol       Date:  2016-11-24

4.  Association between the concentration of imatinib in bone marrow mononuclear cells, mutation status of ABCB1 and therapeutic response in patients with chronic myelogenous leukemia.

Authors:  Chang-Xin Yin; Wei-Wei Chen; Qing-Xiu Zhong; Xue-Jie Jiang; Zhi-Xiang Wang; Xiao-Dong Li; Jie-Yu Ye; Rui Cao; Li-Bing Liao; Fu-Qun Wu; Dan Xu; Jian-Sheng Zhong; Fan-Yi Meng
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

5.  New effective inhibitors of the Abelson kinase.

Authors:  George A Kraus; Vinayak Gupta; Marjan Mokhtarian; Samir Mehanovic; Marit Nilsen-Hamilton
Journal:  Bioorg Med Chem       Date:  2010-07-14       Impact factor: 3.641

6.  LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p.

Authors:  Baoming He; Ying Bai; Wei Kang; Xiaoping Zhang; Xiaojian Jiang
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

7.  Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Authors:  Jorge E Cortes; Michele Baccarani; François Guilhot; Brian J Druker; Susan Branford; Dong-Wook Kim; Fabrizio Pane; Ricardo Pasquini; Stuart L Goldberg; Matt Kalaycio; Beatriz Moiraghi; Jacob M Rowe; Elena Tothova; Carmino De Souza; Marc Rudoltz; Richard Yu; Tillmann Krahnke; Hagop M Kantarjian; Jerald P Radich; Timothy P Hughes
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

8.  Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase.

Authors:  Mervat Mattar
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

Review 9.  miRNAs as Biomarkers in Chronic Myelogenous Leukemia.

Authors:  Kasuen Kotagama; Yung Chang; Marco Mangone
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

10.  Hematologic Relapse after 2 Years on a Non-Authorized Copy Version of Imatinib in a Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report.

Authors:  Zoubir Chouffai
Journal:  Case Rep Oncol       Date:  2010-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.